Ziylo acquired by Novo Nordisk in deal that could exceed US$800m

Ziylo’s technology platform could accelerate the development of a groundbreaking treatment for diabetes patients

A new company, Carbometrics, has been set up to develop novel diagnostics and glucose monitoring

BRISTOL, UK 17 August 2018 ­– Unit DX, the scientific incubator in Bristol announces that its member Ziylo has been acquired by global healthcare company Novo Nordisk A/S in an agreement that could exceed US$800 million. Ziylo’s innovative technology platform offers the potential to develop glucose responsive insulins, a ground-breaking treatment for diabetes patients worldwide.

Ziylo was co-founded by Dr Harry Destecroix, CEO while finishing his PhD in the Anthony Davis Lab at the University of Bristol. He is also the co-founder of Unit DX, along with Tom Smart, CFO and Keith MacDonald, Chairman.

Read more 

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...